

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues have been identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** ... Janet Robertson

**Date:** 21 October 2020

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer

Issue date: October 2020